Novavax
NVAX
#5846
Rank
NZ$1.83 B
Marketcap
NZ$11.31
Share price
-0.61%
Change (1 day)
-29.32%
Change (1 year)

P/S ratio for Novavax (NVAX)

P/S ratio as of December 2025 (TTM): 1.04

According to Novavax's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -6.78. At the end of 2025 the company had a P/S ratio of 1.36.

P/S ratio history for Novavax from 2001 to 2025

PS ratio at the end of each year

Year P/S ratio Change
20251.36-30.27%
20241.94136.46%
20230.822231.11%
20220.6271-93.35%
20219.44-36.78%
202014.9116.33%
20196.90-66.56%
201820.638.17%
201714.9-32.93%
201622.3-64.37%
201562.535.26%
201446.2-9.57%
201351.1303.3%
201212.728.42%
20119.86-98.75%
2010787-4.14%
2009821567.88%
2008123-22.27%
2007158192.21%
200654.189.67%
200528.597.4%
200414.4-18.25%
200317.7286.66%
20024.57-66.51%
200113.6

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Agenus
AGEN
1.18 14.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
0.9685-6.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
0.8663-16.50%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
2.62 152.73%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
4.87 369.66%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
2.31 122.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
4.60 343.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
2.33 124.22%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
682 65,622.80%๐Ÿ‡บ๐Ÿ‡ธ USA